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Globally, there has been substantial scale-up of human im-
munodeficiency virus (HIV) testing services and antiretroviral 
therapy (ART), and it is now estimated that 78% (16 million) of 
the 20.6 million people living with HIV in eastern and south-
ern Africa are receiving treatment.1 As a result, countries or 
districts with high HIV prevalence in sub-Saharan Africa are 
now finding a decline in positivity (that is, the proportion of 
people tested who are positive) in their national HIV testing 
programmes.2–5 For example, an analysis of over 13 million 
tests conducted primarily in health facilities in Kenya between 
July 2017 and June 2018 found that only 1.4% were positive.6 
This figure compares with a national HIV prevalence in adults 
of 4.5% (1 390 000 people in the population of 30 888 880) 
in 2019.7 In seven out of 10 African nations with adult HIV 
prevalence of 10% and above, the positivity from the national 
HIV testing programme has been reported as 5% or below.2 In 
Malawi, for example, the proportion of people found to be HIV 
positive in national testing services has declined from 13.0% 
(170 040) of 1 304 707 people tested in 2008 to 3.1% (139 702) 
of 4 474 393 people in 2018, while the annual number of tests 
conducted has tripled (Fig. 1; A Jahn, Ministry of Health, 
Malawi, unpublished data, 2020). Over the same period, the 
estimated proportion of people living with HIV who were 
receiving ART increased from 14.3% (143 350 of 1 000 000 
people) to 76.9% (769 179 of 1 000 000 people).8
This trend is encouraging, as it signals rapid progression 
towards the global 95–95–95 goals for reducing HIV-associat-
ed mortality and achieving and sustaining low HIV incidence.9 
Nevertheless, as more people living with HIV are diagnosed 
and access treatment, finding people with undiagnosed HIV 
becomes progressively more difficult and expensive.5 Provider-
initiated testing and counselling approaches were recom-
mended by the World Health Organization (WHO) in 2007.10 
At that time, positivity in national HIV testing programmes 
either reflected the prevalence in the general population, such 
as healthy women attending antenatal clinics, or the much 
higher prevalence in those attending tuberculosis or sexually 
transmitted disease services.
In this article we discuss the use of a new indicator, which 
we named treatment-adjusted prevalence. The indicator serves 
as a practical benchmark for the expected yield of HIV positiv-
ity in an adult testing programme when accounting for both 
national HIV prevalence and ART coverage. We chose the label 
treatment-adjusted over status awareness-adjusted as it is the 
aim of HIV programming to achieve virtual elimination of 
disease, and it is only once ART is initiated that viral load de-
clines and onward transmission decreases.9 By explaining the 
application of this indicator with examples from sub-Saharan 
Africa, we hope to promote its use by national programmes 
and implementing organizations at subnational level.
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Abstract Scale-up of human immunodeficiency virus (HIV) testing and antiretroviral therapy (ART) for people living with HIV has been 
increasing in sub-Saharan Africa. As a result, areas with high HIV prevalence are finding a declining proportion of people testing positive in 
their national testing programmes. In eastern and southern Africa, where there are settings with adult HIV prevalence of 12% and above, 
the positivity from national HIV testing services has dropped to below 5%. Identifying those in need of ART is therefore becoming more 
costly for national HIV programmes. Annual target-setting assumes that national testing positivity rates approximate that of population 
prevalence. This assumption has generated an increased focus on testing approaches which achieve higher rates of HIV positivity. This 
trend is a departure from the provider-initiated testing and counselling strategy used early in the global HIV response. We discuss a new 
indicator, treatment-adjusted prevalence, that countries can use as a practical benchmark for estimating the expected adult positivity in a 
testing programme when accounting for both national HIV prevalence and ART coverage. The indicator is calculated by removing those 
people receiving ART from the numerator and denominator of HIV prevalence. Treatment-adjusted prevalence can be readily estimated from 
existing programme data and population estimates, and in 2019, was added to the World Health Organization guidelines for HIV testing and 
strategic information. Using country examples from Kenya, Malawi, South Sudan and Zimbabwe we illustrate how to apply this indicator 
and we discuss the potential public health implications of its use from the national to facility level.
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Challenges
The expectation that the prevalence of 
HIV in adults can be used to approxi-
mate HIV positivity has resulted in an 
increased focus on ways to increase the 
yield of HIV testing services.11–17 Such 
focused, high-risk, high-yield approach-
es are important in HIV programmes, 
but may not provide the volume of 
cost-efficient testing needed in sub-
Saharan Africa to reach the majority of 
people with unidentified HIV infection.5 
Declining HIV positivity, now a wide-
spread finding in many national testing 
programmes, has led several countries 
in sub-Saharan Africa to start imple-
menting risk-screening tools. The aim 
is to shift away from provider-initiated 
testing, to strategies which prioritize 
testing only for those most likely to test 
HIV positive.18–22 To date, such strategies 
have had variable results, with some pro-
grammes reporting that screening tools 
are missing too many people living with 
HIV who would otherwise have been 
tested under provider-initiated testing.
In the context of enhanced qual-
ity assurance and quality control ef-
forts,4,23–25 many national HIV pro-
grammes in sub-Saharan Africa have 
begun reviewing the performance 
of their testing strategies.26–28 These 
countries have also adopted the WHO 
recommended three-test strategy, which 
requires three consecutive reactive tests 
to provide a positive diagnosis and 
enables programmes in all settings to 
achieve at least a 99% positive predictive 
value despite declining HIV positivity.2
With this progress in coverage of 
testing services, HIV programmes in 
sub-Saharan Africa should interpret 
national and subnational data and use 
it to guide decision-making. Countries 
need to consider how the rising propor-
tions of people living with HIV who are 
aware of their HIV status and receiving 
ART will result in declining positivity 
and fewer undiagnosed people in need 
of testing services.
The challenge faced by decision-
makers is how to determine appropriate 
benchmarks for the yield of HIV test-
ing that can be applied to programme 
management and target-setting. Any 
indicator would need to be readily 
understood and applied across the 
national programme, including facil-
ity- and community-based services 
and the higher administrative levels, 
and including donor partner-supported 
programmes. As illustrated in Fig. 1, 
a declining yield of testing may not 
necessarily be an indicator of declin-
ing programme performance but may 
be a reflection that treatment coverage 
is reaching saturation. The concept of 
treatment-adjusted prevalence thus 
characterizes the remaining number of 
undiagnosed people living with HIV in 
a population. This approach could help 
programmes to measure their testing 
yield, while also considering awareness 
of HIV status and ART coverage among 
people living with HIV.
Treatment-adjusted 
prevalence
Treatment-adjusted prevalence (TAP) is 
a way of removing those receiving ART 
from the numerator and denominator 
of HIV prevalence and can be readily 
estimated from existing programme 










where H is number of adults living with 
HIV, A is number of adults living with 
HIV and receiving ART and P is total 
adult population. The indicator has 
been adopted by WHO in its strategic 
information and guidance on HIV 
testing services2,3 and is included in its 
HIV testing services dashboard for 45 
priority countries.29 Anecdotal reports, 
however, indicate that treatment-adjust-
ed prevalence has not yet been widely 
applied at national or subnational level 
to guide decision-making. This lack of 
adaption may be due in part to the dis-
ruption of the coronavirus disease 2019 
pandemic but also to the time it takes 
Fig. 1. Proportion of the adult population positive for HIV infection in the national testing programme, Malawi, 2019
























































ART: antiretroviral therapy; HIV: human immunodeficiency virus.
Source: We obtained the data from the Malawi Ministry of Health.
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for diffusion of innovation. We compare 
the application of this indicator in differ-
ent settings, using population data from 
western Kenya, Malawi, South Sudan and 
Zimbabwe, and we discuss the potential 
public health implications. We selected 
these four countries for this analysis to 
illustrate the utility of treatment-adjusted 
prevalence across countries with differing 
HIV epidemics (Box 1). 
For example, in Zimbabwe in 2018, 
implementing partners reported an 
average testing yield of 5.1% (61 619 of 
1 197 113 people) in provider-initiated 
testing they supported (B Makunike-
Chikwinya, International Training and 
Education Center for Health, unpub-
lished data, 2018). This compares with 
an estimated adult national prevalence 
of 12.8% (1 270 000 of 9 921 875 adults) 
in 2019.30 Yet, in a context where ART 
coverage approached 80% of all people 
living with HIV, determining programme 
performance and effectiveness in light 
of 6.0% testing positivity was difficult.31 
An appropriate benchmark to compare 
against was needed. Using treatment-
adjusted prevalence, we can determine 
that the yield from provider-initiated 
testing was double that of the remaining 
HIV prevalence in the adult population 
not receiving ART. Similarly, in the first 
quarter of 2019, implementing partners 
in Nyanza province, Kenya, reported an 
overall yield of 0.8% in provider-initiated 
testing (K De Cock, United States Cen-
ters for Disease Control and Prevention, 
unpublished data, 2019). The province is 
the highest burden area of the country, 
with an estimated population HIV preva-
lence of 12.7% (compared with Kenya’s 
overall 4.5% prevalence), and with an 
estimated 367 000 (74.9%) of all 490 000 
adults living with HIV receiving ART.7 
In these examples of high levels of both 
HIV testing and ART coverage, adult 
HIV prevalence and testing yield do not 
provide enough information to evaluate 
the overall efficiency and impact of HIV 
testing services.
To understand the low testing yield 
found in western Kenya, we applied the 
same logic used in Zimbabwe in 2018 to 
identify the treatment-adjusted preva-
lence for Nyanza province (Table 1). 
This approach uses the following data: 
(i) census estimate of the adult popula-
tion; (ii) modelled estimate of the num-
ber of adult people living with HIV; and 
(iii) estimated number of adult people 
living with HIV receiving ART. Both the 
numerator and denominator could be 
taken from multiple sources, including 
programme data and population-based 
HIV impact assessment survey data. 
However, for the purpose of this demon-
stration, we used the Spectrum model-
ling software of the Joint United Nations 
Programme on HIV/AIDS to estimate 
HIV prevalence and ART coverage.8 
Children should be excluded from both 
the numerator and denominator as prev-
alence tends to be proportionally much 
lower in children than adults, and only 
a very low proportion of HIV testing in 
children younger than 15 years happens 
outside of prevention of mother-to-child 
transmission programmes.
In the case of western Kenya, when 
the adult population who are receiving 
ART is removed from the numerator and 
denominator, the treatment-adjusted 
prevalence is 3.5% (3.0% in women 
and 4.1% in men), less than a third of 
the 12.7% adult prevalence estimate 
(Table 1).8 Fig. 2 illustrates how the 
overall prevalence of adults living with 
HIV is divided into those receiving ART 
and not receiving ART. Those not receiv-
ing ART include those who do not yet 
know their HIV status, those who know 
their status but have not started treat-
ment, and those who were previously 
receiving ART but have defaulted from 
Box 1. Profile of HIV infection in four sub-Saharan African countries
In Kenya (adult population: 30 888 800), 1 390 000 adults (4.5%) were positive for HIV infection 
in 2019 according to UNAIDS estimates.8 The proportion of adults living with HIV who were 
receiving ART was 75.0% (1 042 164 people). HIV prevalence in the counties around Lake Victoria 
(formerly known as Nyanza province) was 12.7% (490 000 of 3 858 268 adults), making this the 
highest burden area in the country.7
Malawi (adult population: 11 235 955) also has a generalized HIV epidemic, with the health 
ministry reporting an estimated 1 000 000 people infected with HIV, a national prevalence of 
8.9% in 2019. Prevalence was higher in the Southern region and urban areas (17.7% in Blantyre 
city, for example). Nationwide ART coverage was 78.5% (784 948 people).8
In comparison, South Sudan (adult population: 7 320 000) had an estimated national HIV 
prevalence of only 2.5% (183 000 people) in 2019 and ART coverage of 18.2% (33 253 people), 
according to data from UNAIDS.8 
Zimbabwe (adult population: 9 921 875) has high HIV prevalence, with health ministry reports 
in 2019 estimating 12.8% of adults were HIV infected (1 270 000 people). Nationwide coverage 
of ART in adults was 79.8% (1 014 039).8
ART: antiretroviral therapy; HIV: human immunodeficiency virus; UNAIDS: Joint United Nations 
Programme on HIV/AIDS.
Table 1. Calculation of treatment-adjusted prevalence of HIV infection in the adult 
population aged 15–49 years in Nyanza province, western Kenya, 2019
Variable Women Men All adultsa
Total population, extrapolatedb 2 013 423 1 862 745 3 858 268
No. of people living with HIVc 300  000 190 000 490 000
Population HIV prevalence, %c 14.9 10.2 12.7
No. of people receiving ARTc 247 000 119 000 367 000
Treatment coverage, %d 82.3 62.6 74.9
Total population not receiving ARTe 1 766 423 1 743 745 3 491 268
No. of people living with HIV not 
receiving ARTf
53 000 71 000 123 000
Treatment-adjusted prevalence, %g 3.0 4.1 3.5
ART: antiretroviral therapy; HIV: human immunodeficiency virus; UNAIDS: Joint United Nations Programme 
on HIV/AIDS.
a  Extrapolation may result in inconsistencies.
b  Derived by extrapolation from UNAIDS estimates of number of adults living with HIV and prevalence of 
HIV.7,8
c  UNAIDS 2019 estimates.7,8
d  Calculated from number of adults receiving ART as a proportion of number of adults living with HIV.
e  Calculated by subtracting number of adults receiving ART from total adult population.
f  Calculated by subtracting number of adults receiving ART from number of adults living with HIV.
g  Calculated from number of adults living with HIV not receiving ART as a percentage of total adult 
population not receiving ART.
Notes: For this analysis we only used data from the Spectrum modelling software of UNAIDS.7 Kenya has 
moved its administration to subnational county units rather than provinces; Spectrum data still reflect 
provincial estimates within which specific counties can be aligned. 
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care. The 2.5% of the total population 
who are classified as people living with 
HIV not receiving ART becomes the 
3.5% treatment-adjusted prevalence 
once adults receiving ART are removed 
from the equation.
In Table 2, we applied the same 
approach to the South Sudan and 
Zimbabwe estimates.7 HIV prevalence 
in South Sudan was 2.5%, much lower 
than the 12.8% documented in Zimba-
bwe. However, treatment coverage was 
higher in Zimbabwe (79.8%) than South 
Sudan (18.2%) and therefore, despite 
substantial differences in national HIV 
prevalence, both countries have below 
3% treatment-adjusted prevalence of 
HIV in adults. South Sudan’s low ART 
coverage was similar to the coverage in 
Kenya, Malawi and Zimbabwe in the 
early 2000s, when ART coverage was just 
beginning to scale up. This result dem-
onstrates that treatment-adjusted preva-
lence is comparable to HIV prevalence 
in countries with low ART coverage, but 
provides a marked contrast in countries 
with high ART coverage.
Practical application
Selecting algorithms 
The positive predictive value of any 
screening test is “the probability that 
people with a positive result indeed do 
have the condition of interest.”3 WHO 
standards require all HIV tests to have at 
least 99% sensitivity and 98% specificity 
and are used in an HIV testing algorithm 
that achieves at least 99% positive pre-
dictive value. In practical terms, this 
means that there should be no more 
than one false positive per 100 positive 
diagnoses, an error which has serious 
consequences for both individuals and 
the population.2
To maintain such a high-quality 
testing service, mathematical modelling 
32 showed that countries with adult HIV 
prevalence of 5% or higher could achieve 
a 99% positive predictive value by using 
two consecutive reactive tests (two-test 
Fig. 2. Treatment-adjusted prevalence of HIV infection in adults aged 15–49 years in Nyanza province, Kenya, 2019
HIV-negative people
People living with HIV
HIV-negative people
People receiving ART
People not receiving ART
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ART: antiretroviral therapy; HIV: human immunodeficiency virus.
Note: See Table 1 for numerators and denominators for percentages. 
Source: We obtained the data from the Kenyan Ministry of Health.
Table 2. Comparison of treatment-adjusted prevalence of HIV infection in the adult population aged 15–49 years in western Kenya, 
Malawi, South Sudan and Zimbabwe, 2019
Variable Western Kenya Kenya Malawi South Sudan Zimbabwe
Total population, extrapolateda 3 858 268 30 888 800 11 235 955 7 320 000 9 921 875
No. of people living with HIVb 490 000 1 390 000 1 000 000 183 000 1 270 000
Population HIV prevalence, %b 12.7 4.5 8.9 2.5 12.8
No. of people receiving ARTb 367 000 1 042 164 784 948 33 253 1 014 039
Treatment coverage, %c 74.9 75.0 78.5 18.2 79.8
Total population not receiving ARTd 3 491 268 29 846 636 10 451 007 7 286 747 8 907 836
No. of people living with HIV not 
receiving ARTe
123 000 347 836 215 052 149 747 255 961
Treatment-adjusted prevalence, %f 3.5 1.2 2.1 2.1 2.9
ART: antiretroviral therapy; HIV: human immunodeficiency virus; UNAIDS: Joint United Nations Programme on HIV/AIDS.
a  Derived by extrapolation from UNAIDS estimates of number of adults living with HIV and adult prevalence of HIV.7,8
b  UNAIDS 2019 estimates.7,8
c  Calculated from number of adults receiving ART as a proportion of number of adults living with HIV.
d  Calculated by subtracting number of people receiving ART from total population.
e  Calculated by subtracting number of people receiving ART from number of people living with HIV.
f  Calculated from number of people living with HIV not receiving ART as a percentage of total population not receiving ART.
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strategy) to provide a positive diagnosis. 
However, for countries with adult HIV 
prevalence less than 5%, to achieve a 
99% positive predictive value, three con-
secutive reactive tests (three-test strategy) 
were needed to provide a positive diag-
nosis. These WHO-recommended HIV 
testing strategies were first developed 
in 1997, when national prevalence was 
an acceptable indicator for determining 
which testing strategy a country should 
use. Since then, due to successful scale-
up of HIV testing and ART coverage in 
sub-Saharan Africa, HIV epidemiology 
has changed, becoming more heteroge-
neous. Positivity in HIV testing services 
is well below 5% and declining in nearly 
all sub-Saharan Africa programmes.2,3 
As a result, in 2019 WHO recommended 
all countries adopt a standard three-test 
strategy to ensure high-quality testing 
even in populations and settings within 
countries with HIV positivity 5% or less.3 
Countries can use treatment-adjusted 
prevalence as a method to determine 
when to transition to the three-test strat-
egy based on the treatment-adjusted HIV 
prevalence derived by removing those 
receiving ART from the numerator and 
denominator.
Setting targets 
Using treatment-adjusted prevalence 
as a benchmark will allow HIV pro-
grammes to assess their effectiveness in 
targeted testing. The information can 
be readily used to analyse the quality 
and precision of targeted HIV testing 
services in each country and to improve 
the efficiency and effectiveness of testing 
approaches. For example, in Zimbabwe, 
the positivity observed in routine clini-
cal testing was more than twice that of 
the treatment-adjusted prevalence, 
despite being less than half the overall 
adult HIV prevalence. This finding indi-
cated that provider-initiated testing and 
counselling was still a high-yield, cost-
efficient testing strategy. Treatment-
adjusted prevalence facilitated feasible 
target-setting for testing programmes 
both in terms of the volume of tests to 
be conducted and a more accurate esti-
mate of the minimum number of HIV-
positive people who would be identified 
and subsequently linked to care. This 
outcome meant that the country was 
also able to estimate treatment costs for 
the following year more accurately.
Additionally, the indicator can as-
sist in prioritizing resources to those 
subnational levels (districts, counties 
or states) which have variations in both 
HIV prevalence and in treatment cov-
erage. Treatment-adjusted prevalence 
essentially controls for those variations 
at the subnational level in the same way 
as shown at the national level (Table 2).
Identifying shortfalls
In subnational areas and even health 
facility catchment areas where the 
observed testing yield is below the esti-
mated treatment-adjusted prevalence, 
testing programmes could be reviewed 
to see if more effective approaches can be 
implemented. As described above, in the 
western Kenya counties that formerly 
made up Nyanza province, positivity 
in routine HIV testing in clinical set-
tings (0.8%) was less than a third of 
the treatment-adjusted HIV prevalence 
(3.5%). These data indicate a need for 
further investigation into how well 
routine testing practices are aligned with 
national and global guidance.2 Our rapid 
assessment (B Tippett Barr, Center for 
Global Health, Kenya, unpublished data, 
2019) revealed that provider-initiated 
testing was not routinely offered at all 
service delivery points as per global 
guidance. Although available at patient 
registration points, patient testing re-
quired as much initiative on the part of 
the patient as the provider. However, in 
antenatal settings in the same facilities 
where provider-initiated testing was 
routinely implemented according to 
global guidance, HIV test positiv-
ity exceeded the treatment-adjusted 
prevalence in antenatal care. These 
findings further reinforce the concept 
of treatment-adjusted prevalence as a 
lower bound for effective testing strate-
gies. If the women attending antenatal 
care are mostly healthy and represent a 
cross-section of society, logically their 
HIV prevalence should be lower than 
those who are attending a health facil-
ity with an illness. The conclusion we 
drew was that inconsistent offers of HIV 
testing in non-antenatal care settings 
in health facilities in western Kenya 
was not a cost-effective or productive 
strategy. One should note that low test 
positivity in non-antenatal care settings 
does not negate the need for provider-
initiated testing; it may instead indicate 
that such testing is not being correctly 
implemented. As in Zimbabwe,31 when 
we conducted a careful review of site-
level implementation and closed gaps in 
consistency and service delivery points, 
test positivity increased markedly. These 
experiences from Kenya and Zimbabwe 
illustrate how treatment-adjusted preva-
lence can be a practical benchmark for 
the lower bound of expected HIV posi-
tivity in any testing setting, particularly 
during an era of increasingly targeted 
testing to improve case identification.
Limitations
As described above, a limitation of the 
new indicator is that it does not account 
for the proportion of individuals who 
already knew their HIV status and chose 
not to disclose that information during 
HIV testing, therefore artificially inflat-
ing the treatment-adjusted prevalence. 
Studies have reported that 13–68% of 
patients known to be positive seek re-
testing before starting ART.33–36 Anec-
dotal reports also reveal that individuals 
already receiving ART occasionally 
re-test for personal reasons. However, 
based on field experience across multiple 
countries, we do not believe the propor-
tions of people re-testing after starting 
ART exceeds the proportion re-testing 
before ART. The limitation of including 
people known to be HIV positive but 
seeking repeat testing does then not de-
tract from the usefulness of treatment-
adjusted prevalence as a lower bound for 
the expected yield of testing. An addi-
tional limitation to this indicator is that 
it excludes individuals younger than 15 
years. Other approaches are needed to 
improve the targeting and performance 
of HIV testing programmes for children. 
National or subnational treatment-
adjusted prevalence estimates are also 
not applicable to key populations (such 
as men who have sex with men or fe-
male sex workers), as these population 
subgroups have consistently higher HIV 
prevalence and often lower ART cover-
age than the general adult population.
We developed treatment-adjusted 
prevalence primarily to address ques-
tions emerging in sub-Saharan Africa; 
its utility has not yet been demonstrated 
for priority subpopulations or for other 
settings. The logic applied in this indica-
tor is transferable to other settings and 
populations but, as with all estimates, 
the validity of the point estimate would 
depend on the accuracy of the estimates 
used. In all settings and populations, 
when treatment-adjusted prevalence is 
applied at subnational levels, and by de-
fault applied to smaller numbers, there 
will be increasing uncertainty around 
the point estimate produced.
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Conclusion
Treatment-adjusted HIV prevalence is 
a practical and simple indicator con-
structed from readily available data, 
which could guide the selection of 
national HIV testing algorithms and 
hence improve programme manage-
ment and monitoring. This indicator, 
adopted by WHO, provides a lower 
bound for expected HIV testing yield 
in settings where coverage of ART is 
high. The adjustment may result in 
more appropriate HIV testing services 
and treatment targets and may help 
evaluate performance in heterogeneous 
populations. The indicator helps focus 
HIV testing programmes on people with 
undiagnosed HIV and on individuals 
known to be positive but who are not 
receiving ART. Nevertheless, treatment-
adjusted prevalence should not detract 
from the additional focus on testing 
approaches for subpopulations with 
higher HIV risk.
Depending on the quality of data 
available in a country, treatment-ad-
justed prevalence could also be disag-
gregated at subnational levels, by sex or 
by age group. Furthermore, the indicator 
may be useful for monitoring the global 
HIV response and for prioritizing geo-
graphical regions, as it can be routinely 
derived when countries conduct their 
annual HIV modelling estimates. The 
development and practical application 
of indicators such as treatment-adjusted 
prevalence will become increasingly 
important as HIV treatment coverage 
approaches 100%. ■
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人体免疫缺陷病毒 (HIV) 检测和抗逆转录病毒治疗 
(ART) 的规模正在不断扩大。结果发现 , 国家检测计
划实施期间 , 在艾滋病患病率高发的地区 , 检测呈阳性
的人数比例正在下降。在东非和北非 , 成人艾滋病患
病率超过 12% 的地方 , 国家艾滋病检测计划中的阳性
















معدل االنتشار القائم عىل ضبط العالج لتقييم برامج اختبار فريوس نقص املناعة البرشية
 (HIV) البرشية  املناعة  نقص  فريوس  اختبار  نطاق  تزايد  لقد 
لألشخاص   (ART) القهقرية  للفريوسات  املضاد  والعالج 
الصحراء  جنوب  يف  البرشية  املناعة  نقص  فريوس  مع  املتعايشني 
انتشار  فيها  يزيد  التي  املناطق  فإن  لذلك،  نتيجة  بأفريقيا.  الكربى 
متناقصة من األشخاص  نسبة  لدهيا  البرشية  املناعة  نقص  فريوس 
الذين ثبتت إصابتهم بالفريوس يف برامج االختبار الوطنية لدهيم. 
انتشار  فيها  يصل  بيئات  توجد  حيث  إفريقيا،  وجنوب  رشق  يف 
وما   12% نسبة  إىل  البالغني  بني  البرشية  املناعة  نقص  فريوس 
فريوس  الختبار  الوطنية  اخلدمات  من  اإلجيابية  انخفضت  فوق، 
من  حتديد  أصبح  ولذلك   .5% من  أقل  إىل  البرشية  املناعة  نقص 
هم بحاجة إىل العالج املضاد للفريوسات القهقرية (ART) أكثر 
البرشية.  املناعة  نقص  لفريوس  الوطنية  للربامج  بالنسبة  تكلفة 
االختبار  إجيابية  معدالت  أن  السنوي  اهلدف  حتديد  يفرتض 
االفرتاض  هذا  أدى  السكاين.  االنتشار  معدالت  تقارب  الوطنية 
أعىل  معدالت  حتقق  التي  االختبار  أساليب  عىل  الرتكيز  زيادة  إىل 
خروج  هو  االجتاه  هذا  البرشية.  املناعة  نقص  فريوس  إجيابية  من 
اخلدمة،  مقدم  بدأها  التي  واالستشارة  االختبار  اسرتاتيجية  عن 
املناعة  نقص  لفريوس  العاملية  االستجابة  يف  مبكًرا  واملستخدمة 
عىل  القائم  االنتشار  وهو  جديًدا،  مؤرًشا  نناقش  نحن  البرشية. 
عميل  كمعيار  استخدامه  للدول  يمكن  والذي  العالج،  ضبط 
التعبري  عند  االختبار  برنامج  يف  للبالغني  املتوقعة  اإلجيابية  لتقدير 
الوطني،  املستوى  عىل  البرشية  املناعة  نقص  فريوس  انتشار  عن 
عن  املؤرش  حساب  يتم  القهقرية.  للفريوسات  املضادة  والتغطية 
طريق حذف األشخاص الذين يتلقون العالج املضاد للفريوسات 
البرشية.  املناعة  نقص  فريوس  انتشار  ومقام  بسط  من  القهقرية 
يمكن تقدير االنتشار القائم عىل ضبط العالج بسهولة من بيانات 
الربنامج احلالية وتقديرات السكان، ويف عام 2019، متت إضافته 
إىل إرشادات منظمة الصحة العاملية الختبار فريوس نقص املناعة 
البرشية واملعلومات االسرتاتيجية. وباستخدام أمثلة من الدول من 
كينيا ومالوي وجنوب السودان وزيمبابوي، نوضح كيفية تطبيق 
هذا املؤرش، ونناقش اآلثار املحتملة عىل الصحة العامة الستخدامه 
من املستوى الوطني إىل مستوى املرفق.
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Évaluation des programmes de dépistage du VIH à l'aide de la prévalence ajustée sur le traitement
Le dépistage du virus de l'immunodéficience humaine (VIH) et le 
traitement antirétroviral (TAR) pour les personnes vivant avec le VIH ont 
connu un véritable essor en Afrique subsaharienne. Par conséquent, 
les régions touchées par une forte prévalence du VIH détectent un 
pourcentage moins élevé de personnes testées positives dans leurs 
programmes de dépistage nationaux. En Afrique orientale et australe, 
là où certains endroits affichent une prévalence du VIH chez l'adulte 
égale ou supérieure à 12%, le taux de positivité des services de dépistage 
nationaux est passé sous la barre des 5%. Identifier les personnes 
nécessitant un TAR devient donc plus coûteux pour les programmes 
nationaux consacrés au VIH. Pour définir les objectifs annuels, on 
part du principe que les taux de positivité nationaux se rapprochent 
du taux de prévalence au sein de la population. Cette supposition a 
orienté les démarches vers des méthodes de dépistage permettant 
d'obtenir des taux de positivité plus élevés; une tendance qui s'écarte 
de la stratégie des services de dépistage et de conseil à l'initiative des 
prestataires, utilisée à l'aube de la lutte mondiale contre le VIH. Dans 
le présent document, nous nous intéressons à un nouvel indicateur, 
la prévalence ajustée sur le traitement. Cet indicateur peut servir de 
référence concrète pour les pays qui souhaitent évaluer le taux de 
positivité attendu chez l'adulte dans un programme de dépistage, en 
tenant compte de la prévalence du VIH au niveau national ainsi que de 
la portée du TAR. Le calcul consiste à enlever les personnes recevant 
un TAR du numérateur et du dénominateur de la prévalence du VIH. 
La prévalence ajustée sur le traitement peut aisément être déterminée 
en fonction des données de programme et estimations de population 
existantes. En 2019, elle a également été ajoutée aux lignes directrices 
de l'Organisation mondiale de la Santé pour l'information stratégique 
et le dépistage du VIH. En nous inspirant d'exemples issus du Kenya, du 
Malawi, du Soudan du Sud et du Zimbabwe, nous expliquons comment 
employer cet indicateur et abordons les potentielles implications liées 
à son utilisation en matière de santé publique, en partant du niveau 
national jusqu'aux établissements.
Резюме
Доля ВИЧ-инфицированного населения с поправкой на лечение при оценке программ тестирования на 
ВИЧ
Расширение масштабов тестирования на вирус иммунодефицита 
человека (ВИЧ) и антиретровирусной терапии (АРТ) для людей, 
живущих с ВИЧ, увеличивается в странах Африки к югу от 
Сахары. В результате в регионах с высокими показателями 
распространения ВИЧ наблюдается снижение доли населения 
с положительным результатом теста в рамках национальных 
программ тестирования. В восточной и южной частях Африки, где 
распространенность ВИЧ среди взрослого населения составляет 
12% и выше, положительные результаты теста на ВИЧ в рамках 
национальных программ тестирования опустились ниже 5%. 
Таким образом, выявление лиц, нуждающихся в АРТ, становится 
более дорогостоящим для национальных программ по борьбе 
с ВИЧ. Ежегодная постановка целей предполагает, что процент 
лиц с положительным результатом теста в рамках национальных 
программ тестирования приблизительно соответствует 
проценту распространенности среди населения в целом. Это 
предположение вызвало повышенное внимание к методам 
тестирования, которые достигают более высоких показателей 
распространенности ВИЧ-инфекции. Эта тенденция является 
отступлением от стратегии тестирования и консультирования 
по инициативе поставщиков услуг, которая использовалась на 
раннем этапе глобальных мер борьбы с ВИЧ. Авторы обсуждают 
новый показатель распространенности с поправкой на лечение, 
который страны могут использовать в качестве практического 
ориентира для оценки ожидаемого процента взрослого 
населения с положительным результатом теста в рамках 
программы тестирования с учетом как распространенности 
ВИЧ на национальном уровне, так и охвата АРТ. Показатель 
рассчитывается путем исключения лиц, получающих АРТ, из 
числителя и знаменателя доли ВИЧ-инфицированного населения. 
Долю ВИЧ-инфицированного населения с поправкой на лечение 
можно легко оценить на основе существующих данных по 
программе и демографических оценок, которые в 2019 году 
были добавлены в рекомендации Всемирной организации 
здравоохранения по тестированию на ВИЧ и стратегической 
информации. Используя примеры из Зимбабве, Кении, Малави 
и Южного Судана, авторы проиллюстрируют применение 
этого показателя, а также обсудят возможные последствия 
его использования для общественного здравоохранения на 
национальном уровне и уровне учреждения.
Resumen
Prevalencia ajustada según el tratamiento para evaluar los programas de las pruebas de detección del VIH
La ampliación de las pruebas de detección del virus de la 
inmunodeficiencia humana (VIH) y del tratamiento antirretrovírico 
(TAR) para las personas infectadas por el VIH ha aumentado en el África 
subsahariana. En consecuencia, el porcentaje de personas que dan 
positivo en las pruebas de detección del VIH en los programas nacionales 
está disminuyendo en las zonas con alta prevalencia del virus. En África 
meridional y oriental, donde hay entornos con una prevalencia del VIH 
en adultos del 12 % o superior, la tasa de positividad de los servicios 
nacionales de pruebas de detección del VIH ha descendido a menos 
del 5 %. Por lo tanto, la identificación de las personas que necesitan 
TAR es cada vez más costosa para los programas nacionales de VIH. El 
establecimiento de objetivos anuales supone que las tasas de positividad 
de las pruebas nacionales se aproximan a las de la prevalencia de la 
población. Esta suposición ha generado una mayor atención a los 
enfoques de las pruebas que logran tasas más altas de positividad del 
VIH. Esta tendencia se aleja de la estrategia del asesoramiento y las 
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pruebas que iniciaron los proveedores y que se utilizó al principio de la 
respuesta mundial al VIH. Se analiza un nuevo indicador, la prevalencia 
ajustada según el tratamiento, que los países pueden emplear como 
punto de referencia práctico para estimar la tasa de positividad esperada 
en adultos en un programa de pruebas de detección cuando se tiene 
en cuenta tanto la prevalencia nacional del VIH como la cobertura del 
TAR. El indicador se calcula eliminando del numerador y el denominador 
de la prevalencia del VIH a las personas que reciben TAR. La prevalencia 
ajustada según el tratamiento se puede estimar con facilidad a partir de 
los datos de los programas existentes y de las estimaciones de población, 
además, en 2019, se incluyó en las directrices de la Organización Mundial 
de la Salud para las pruebas de detección del VIH y en la información 
estratégica. A través de ejemplos de países como Kenia, Malaui, Sudán 
meridional y Zimbabue, se demuestra cómo aplicar este indicador y 
se discuten las posibles implicaciones para la salud pública de su uso 
desde el nivel nacional hasta el de los centros.
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